Drugs / ZMapp
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT02363322 | Mar 2015 → Dec 2017 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT03719586 | Nov 2018 → Sep 2019 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZMapp | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02363322 ↗ |
| Modality | Monoclonal antibody | “triple monoclonal antibody cocktail ZMapp” PMID 27732819 ↗ Oct 2016 |
| Route | Intravenous | “three intravenous infusions of ZMapp” PMID 27732819 ↗ Oct 2016 |